FDA approves Lilly’s Mounjaro (tirzepatide) injection
The US Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide), Eli Lilly and Company’s new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)